Press-release for stocks related to fda for AXSM

Prices are updated after-hours

Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
Published: 2022-09-29 (Crawled : 12:20) - biospace.com/
AXSM | $68.26 -1.29% -1.3% 430K

| 46.15% | O: 0.71% H: 1.26% C: -6.06%
axs-07 fda meeting therapeutics

| 60.76% | O: 22.3% H: 17.77% C: 14.76%
treatment fda approval therapeutics major depressive disorder

| 113.89% | O: -0.5% H: 0.0% C: 0.0%
axs-07 treatment fda drug application therapeutics response migraine

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
Published: 2021-09-14 (Crawled : 12:00) - biospace.com/
AXSM | $68.26 -1.29% -1.3% 430K

| 148.22% | O: 3.53% H: 1.41% C: -8.01%
new drug treatment fda fda acceptance migraine drug application

| 28.97% | O: 10.84% H: 4.9% C: 0.14%
new drug treatment fda fda acceptance drug depression major depressive disorder

49%

51%

KAVL | $6.275 135.02% 57.45% 44M

PXMD | $0.7375 79.09% 44.16% 4.5M

DYNT | $0.371 -5.12% 43.09% 3.3M

LGVN P | $2.94 73.96% 42.52% 57M

HUBC | $1.94 49.23% 32.99% 73M

SPCB | $0.4044 46.52% 31.75% 130M

ONVO | $1.34 32.66% 24.62% 54M

OMQS | $0.6869 32.1% 24.3% 3.6M

SNPO | $10.555 29.67% 22.88% 4M

AMBI | $3.72 -26.77% 21.77% 9.8K

Save your searches and get alerts when important news are released.